111 related articles for article (PubMed ID: 35048632)
1. Evaluation of EZH2 and ERRα in colorectal carcinoma: an immunohistochemical study.
Abou Gabal H; Ahmed N; Meckawy G; Yassin R; Hakim S
Pol J Pathol; 2021; 72(3):200-210. PubMed ID: 35048632
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-related receptors alpha, beta and gamma expression and function is associated with transcriptional repressor EZH2 in breast carcinoma.
Kumari K; Adhya AK; Rath AK; Reddy PB; Mishra SK
BMC Cancer; 2018 Jun; 18(1):690. PubMed ID: 29940916
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
Abdel Raouf SM; Ibrahim TR; Abdelaziz LA; Farid MI; Mohamed SY
J Gastrointest Cancer; 2021 Mar; 52(1):90-98. PubMed ID: 31823218
[TBL] [Abstract][Full Text] [Related]
4. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
[TBL] [Abstract][Full Text] [Related]
7. High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.
Liang R; Lin Y; Yuan CL; Liu ZH; Li YQ; Luo XL; Ye JZ; Ye HH
Oncol Lett; 2018 Apr; 15(4):5933-5939. PubMed ID: 29552224
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Immunohistochemical Expression of Enhancer of Zeste Homolog 2 (EZH2) and Its Association With Clinicopathological Variables in Carcinoma Cervix.
Priya A; Chaurasia JK; K P; Panwar H; Yadav SK; Kapoor N
Cureus; 2023 Mar; 15(3):e36946. PubMed ID: 37131568
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.
Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M
Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.
Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
[TBL] [Abstract][Full Text] [Related]
13. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
[TBL] [Abstract][Full Text] [Related]
14. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.
Yamamoto I; Nosho K; Kanno S; Igarashi H; Kurihara H; Ishigami K; Ishiguro K; Mitsuhashi K; Maruyama R; Koide H; Okuda H; Hasegawa T; Sukawa Y; Okita K; Takemasa I; Yamamoto H; Shinomura Y; Nakase H
Oncotarget; 2017 Mar; 8(11):17810-17818. PubMed ID: 28147317
[TBL] [Abstract][Full Text] [Related]
15. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
Sameh R; Mostafa N; Ramadan M; AbdelRaouf S; Abdelwahab K
J Histotechnol; 2022 Mar; 45(1):21-28. PubMed ID: 34493171
[TBL] [Abstract][Full Text] [Related]
18. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
19. EZH2 expression in invasive lobular carcinoma of the breast.
Roh S; Park SY; Ko HS; Sohn JS; Cha EJ
World J Surg Oncol; 2013 Nov; 11():299. PubMed ID: 24266940
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
